ArkBio Gets FDA Clearance for AK0406 Influenza Prevention Phase II Trial

ArkBio, a Shanghai-based company, received FDA clearance to initiate a Phase II prevention trial of its novel long-acting antiviral drug-Fc conjugate AK0406 targeting influenza A and B, following successful Phase I dosing in Australia and regulatory approval in China.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.